Mineralys Therapeutics, Inc. (MLYS) Stock Analysis and Metrics

Mineralys Therapeutics

NASDAQ: MLYS

$26.73 ▼ -0.27 (-1.00%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.21 Bn

P/E-6.96

Div. Yield0.00

Add ratio to table…

About

Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines that target diseases driven by dysregulated aldosterone. The company’s lead product candidate lorundrostat is an oral aldosterone synthase inhibitor designed to reduce aldosterone levels by inhibiting the CYP11B2 enzyme. Lorundrostat is being advanced for the treatment of hypertension and related cardiorenal conditions such as chronic kidney disease and obstructive sleep apnea. The firm has completed multiple clinical trials demonstrating that lorundrostat lowers systolic blood pressure and improves markers of kidney injury while maintaining a favorable safety profile. The company aims to address a significant unmet need among patients whose blood pressure remains uncontrolled despite standard antihypertensive therapy.

Mineralys Therapeutics, Inc. has not yet generated product revenue because lorundrostat remains in clinical development and awaits regulatory approval. The company’s financial resources to date come from equity financing, having raised approximately 1.1 billion dollars in gross proceeds from the sale of common stock, preferred stock, pre funded warrants and convertible notes since inception. These funds have been used to support research and development activities, clinical trial execution, manufacturing arrangements and general corporate operations. The company plans to seek additional funding as needed to advance lorundrostat through regulatory review and toward potential commercial launch.

Mineralys Therapeutics, Inc. occupies a niche position in the cardiovascular drug development landscape as one of few companies pursuing an aldosterone synthase inhibitor approach. Its main competitors include other firms developing similar agents such as AstraZeneca, Boehringer Ingelheim, Damian Pharma and CORXEL, as well as companies marketing mineralocorticoid receptor antagonists like spironolactone and eplerenone. The broader hypertension treatment market is large, with over one hundred twenty million individuals in the United States diagnosed with elevated blood pressure and a substantial proportion failing to achieve goal levels despite multiple therapies. The company’s potential advantage lies in lorundrostat’s high selectivity for aldosterone over cortisol, which reduces the risk of adrenal insufficiency and related side effects. Additionally, the once daily dosing regimen offers convenience compared with therapies requiring multiple daily doses. Clinical data have shown a favorable tolerability profile with low rates of serious adverse events and limited hyperkalemia occurrences. These attributes may help differentiate lorundrostat from existing mineralocorticoid receptor antagonists that often cause electrolyte disturbances and hormonal side effects.

Mineralys Therapeutics, Inc. intends to serve patients with hypertension, particularly those with uncontrolled or resistant hypertension, as well as patients who have comorbid chronic kidney disease or obstructive sleep apnea. The company’s future customers will include health care providers, health systems and payers that treat these patient populations. Physicians specializing in cardiology, nephrology and primary care are expected to prescribe lorundrostat for eligible patients. Hospitals and outpatient clinics will be points of care where the drug may be administered or prescribed. Insurance companies and government programs such as Medicare and Medicaid will determine coverage and reimbursement levels that influence patient access. By targeting a defined subset of hypertensive patients with underlying aldosterone dysregulation, the company aims to address a segment of the market that remains underserved by current standard of care options.

Investment Thesis

▲ Bull case

The FDA acceptance of the lorundrostat NDA with a PDUFA date set for December 22 2026 provides a clear near term catalyst. This milestone shows that the regulatory path is progressing as expected and reduces uncertainty around approval timing. Given the company's cash runway extends into 2028 the balance sheet can support launch activities without immediate financing pressure. As a result the market may be underpricing the value of imminent commercialization.
The cash position of $646,100,000 as of March 31 2026 provides a solid financial foundation. This amount exceeds the estimated cash burn needed to support operations clinical trials and regulatory activities through 2028. Consequently dilution risk is reduced and there is flexibility to invest in commercial infrastructure. General and administrative spending has increased to support pre launch efforts reflecting a deliberate shift from research to market readiness.
Physician and payer research indicates strong receptivity to lorundrostat with prescribers willing to use it in the fourth line setting. Payers express openness to provide coverage for high risk resistant hypertension patients based on the drug's clinical profile. Patient interest data show a preference for novel agents that deliver sustained blood pressure reduction with tolerable dosing aligning with lorundrostat s once daily oral administration. The high representation of Black African American patients ranging from 28% to 50% across trials addresses a key demographic that is disproportionately affected by resistant hypertension and enhances the drug s relevance to guideline committees focused on health equity.
Beyond hypertension the EXPLORE CKD trial revealed a 9.6 mmHg placebo adjusted systolic blood pressure reduction in chronic kidney disease patients. The same trial showed a greater than 50% reduction in urinary albumin a marker of kidney damage suggesting lorundrostat may have label expansion potential into cardiorenal indications. The aldosterone synthase inhibitor mechanism is increasingly viewed as a therapeutic target for heart failure and chronic kidney disease creating structural growth opportunities for the class independent of hypertension sales. Management s ongoing partnering discussions with a preference for a global partner capable of maximizing lorundrostat s potential in hypertension and related comorbidities hint at possible value accretive collaborations that could accelerate development in these adjacent markets.

The FDA acceptance of the lorundrostat NDA with a PDUFA date set for December 22 2026 provides a clear near term catalyst. This milestone shows that the regulatory path is progressing as expected and reduces uncertainty around approval timing. Given the company's cash runway extends into 2028 the balance sheet can support launch activities without immediate financing pressure. As a result the market may be underpricing the value of imminent commercialization.
The cash position of $646,100,000 as of March 31 2026 provides a solid financial foundation. This amount exceeds the estimated cash burn needed to support operations clinical trials and regulatory activities through 2028. Consequently dilution risk is reduced and there is flexibility to invest in commercial infrastructure. General and administrative spending has increased to support pre launch efforts reflecting a deliberate shift from research to market readiness.
Physician and payer research indicates strong receptivity to lorundrostat with prescribers willing to use it in the fourth line setting. Payers express openness to provide coverage for high risk resistant hypertension patients based on the drug's clinical profile. Patient interest data show a preference for novel agents that deliver sustained blood pressure reduction with tolerable dosing aligning with lorundrostat s once daily oral administration. The high representation of Black African American patients ranging from 28% to 50% across trials addresses a key demographic that is disproportionately affected by resistant hypertension and enhances the drug s relevance to guideline committees focused on health equity.
Beyond hypertension the EXPLORE CKD trial revealed a 9.6 mmHg placebo adjusted systolic blood pressure reduction in chronic kidney disease patients. The same trial showed a greater than 50% reduction in urinary albumin a marker of kidney damage suggesting lorundrostat may have label expansion potential into cardiorenal indications. The aldosterone synthase inhibitor mechanism is increasingly viewed as a therapeutic target for heart failure and chronic kidney disease creating structural growth opportunities for the class independent of hypertension sales. Management s ongoing partnering discussions with a preference for a global partner capable of maximizing lorundrostat s potential in hypertension and related comorbidities hint at possible value accretive collaborations that could accelerate development in these adjacent markets.

▼ Bear case

The imminent approval of AstraZeneca s baxdrostat in the mid 2026 timeframe creates a first mover advantage. This could establish baxdrostat as the reference product for the aldosterone synthase inhibitor class and set pricing and formulary preferences. Payers often favor the first approved agent in a new class due to familiarity and established rebate structures which could limit lorundrostat s access even if its clinical data are strong. The company s pricing strategy remains undefined with management only referencing Farxiga and Jardiance as loose benchmarks leaving uncertainty about whether lorundrostat can achieve a premium or must compete on price.
While the Launch HTN and Advance HTN trials showed meaningful blood pressure reductions the data do not yet demonstrate hard outcome benefits such as reduction in cardiovascular events or renal progression. Payers increasingly require proof of long term value for formulary placement making reliance on surrogate endpoints a potential limitation. Furthermore the open label extension TRANSFORM HTN is still ongoing and long term safety data have not been fully disclosed leaving a potential risk that rare adverse events could emerge after approval. Until definitive outcome data are available the commercial story remains dependent on blood pressure lowering alone which may be insufficient to justify a premium price or broad guideline adoption.
The company s financial runway is predicated on the assumption that current cash reserves will sustain operations into 2028. This projection assumes no unexpected increases in spending or delays in the PDUFA process. A delay in the FDA decision beyond December 2026 would increase cash burn and could necessitate additional financing dilutive to existing shareholders. Furthermore the sizable increase in general and administrative expenses to $21,000,000 reflects a front loaded investment in commercial infrastructure that may not translate into proportional revenue if launch execution falters or market uptake is slower than anticipated. The concentration of value in a single product lorundrostat means any setback in approval labeling or commercialization would have a disproportionate impact on the overall enterprise value.
Partnering discussions remain vague with no disclosed timeline structure or financial terms creating uncertainty about whether Mineralys will secure a global partner capable of maximizing lorundrostat s potential. This uncertainty raises the possibility that the company will be forced to pursue a go it alone strategy that strains its organizational capabilities. The management s stated preference for a global partner with expertise in hypertension and related comorbidities suggests that negotiations may be complex and prolonged potentially delaying access to complementary expertise and commercial networks. If a partnership is not finalized before launch the company would need to build out a full scale sales and marketing organization internally increasing fixed costs and execution risk. Additionally the lack of clarity on potential label expansion into cardiorenal indications means investors cannot model for upside beyond the hypertension market adding to the valuation uncertainty.

The imminent approval of AstraZeneca s baxdrostat in the mid 2026 timeframe creates a first mover advantage. This could establish baxdrostat as the reference product for the aldosterone synthase inhibitor class and set pricing and formulary preferences. Payers often favor the first approved agent in a new class due to familiarity and established rebate structures which could limit lorundrostat s access even if its clinical data are strong. The company s pricing strategy remains undefined with management only referencing Farxiga and Jardiance as loose benchmarks leaving uncertainty about whether lorundrostat can achieve a premium or must compete on price.
While the Launch HTN and Advance HTN trials showed meaningful blood pressure reductions the data do not yet demonstrate hard outcome benefits such as reduction in cardiovascular events or renal progression. Payers increasingly require proof of long term value for formulary placement making reliance on surrogate endpoints a potential limitation. Furthermore the open label extension TRANSFORM HTN is still ongoing and long term safety data have not been fully disclosed leaving a potential risk that rare adverse events could emerge after approval. Until definitive outcome data are available the commercial story remains dependent on blood pressure lowering alone which may be insufficient to justify a premium price or broad guideline adoption.
The company s financial runway is predicated on the assumption that current cash reserves will sustain operations into 2028. This projection assumes no unexpected increases in spending or delays in the PDUFA process. A delay in the FDA decision beyond December 2026 would increase cash burn and could necessitate additional financing dilutive to existing shareholders. Furthermore the sizable increase in general and administrative expenses to $21,000,000 reflects a front loaded investment in commercial infrastructure that may not translate into proportional revenue if launch execution falters or market uptake is slower than anticipated. The concentration of value in a single product lorundrostat means any setback in approval labeling or commercialization would have a disproportionate impact on the overall enterprise value.
Partnering discussions remain vague with no disclosed timeline structure or financial terms creating uncertainty about whether Mineralys will secure a global partner capable of maximizing lorundrostat s potential. This uncertainty raises the possibility that the company will be forced to pursue a go it alone strategy that strains its organizational capabilities. The management s stated preference for a global partner with expertise in hypertension and related comorbidities suggests that negotiations may be complex and prolonged potentially delaying access to complementary expertise and commercial networks. If a partnership is not finalized before launch the company would need to build out a full scale sales and marketing organization internally increasing fixed costs and execution risk. Additionally the lack of clarity on potential label expansion into cardiorenal indications means investors cannot model for upside beyond the hypertension market adding to the valuation uncertainty.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password